Overview We are a biotechnology company developing innovative therapeutics targeting serious viral diseases with the potential to improve the lives of patients worldwide. Our pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPIs) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus (HDV) entry inhibitor; and (3) a highly potent next-generation capsid assembly modulator (CAM)...
Q2 FY2026 — expected 2026-08-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001193125-26-115992 | EDGAR | 68K words |
| 2025-03-20 | 2024-12-31 | 0000950170-25-042673 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0000950170-24-038057 | EDGAR | — |
| 2023-03-22 | 2022-12-31 | 0000950170-23-009184 | EDGAR | — |
| 2022-03-11 | 2021-12-31 | 0001564590-22-009855 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001564590-21-008878 | EDGAR | — |
| 2020-03-04 | 2019-12-31 | 0001564590-20-008696 | EDGAR | — |
| 2019-02-28 | 2018-12-31 | 0001144204-19-011361 | EDGAR | — |
| 2018-03-08 | 2017-12-31 | 0001144204-18-013474 | EDGAR | — |
| 2017-03-02 | 2016-12-31 | 0001144204-17-012234 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001193125-25-274277 | EDGAR | 34K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-104060 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066991 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123402 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093998 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055680 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0000950170-23-061134 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0000950170-23-040626 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017931 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023233 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001564590-22-028763 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001564590-22-019879 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001193125-26-131872 | EDGAR | 1K words |
| 2026-03-19 | 0001193125-26-115980 | EDGAR | — |
| 2025-12-08 | 0001193125-25-311251 | EDGAR | — |
| 2025-11-10 | 0001193125-25-274235 | EDGAR | — |
| 2025-08-11 | 0001193125-25-178092 | EDGAR | — |
| 2025-08-08 | 0001193125-25-176138 | EDGAR | — |
| 2025-08-06 | 0000950170-25-104020 | EDGAR | — |
| 2025-06-25 | 0000950170-25-089949 | EDGAR | — |
| 2025-06-09 | 0000950170-25-083830 | EDGAR | — |
| 2025-05-08 | 0000950170-25-066946 | EDGAR | — |
306 total filings indexed. 274 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001426800 |
| Ticker | ASMB |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.assemblybio.com |
| Listed | 2010-12-17 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report